In the careful calculus of mental health infrastructure, timing is everything. A new clinic cannot open the day a treatment is approved, and a patient cannot find a trusted provider if no directory exists. Pink Elephant, a Lisbon-based venture builder founded in late 2024, is placing its bet on that precise gap. It is not developing a psychedelic molecule or running a therapy clinic. Instead, it is constructing the digital and informational scaffolding,media, diagnostics, provider marketplaces,that a future, more permissive mental health ecosystem would need to function [Pink Elephant].
The model is part investment fund, part company builder, operating across what it calls progressive mental care. Its portfolio includes States of Mind, a media platform for psychedelic news and science, and plans for diagnostic tools and a vetted practitioner directory [Remocate, September 2025] [LinkedIn, retrieved 2026]. The thesis is humane, if speculative: by building trusted navigation and education tools today, Pink Elephant positions itself as a foundational layer for patients and clinicians whenever novel treatments gain wider regulatory acceptance.
Building the ecosystem ahead of the drug
Pink Elephant’s activities are deliberately broad, spanning media, e-commerce, telemedicine, and technology [Remocate, September 2025]. This reflects a venture-building approach rather than a single-product focus. The goal is to expand access to what it terms “safe and scalable progressive mental care” by supporting founders, clinicians, and operators across the ecosystem [Pink Elephant].
A key pillar is its venture fund, which targets pre-seed and seed-stage startups in the US building SaaS for telemedicine, clinics, and therapist tools, with valuations under $8 million [Pink Elephant]. The parallel venture-building arm develops its own projects, like States of Mind, which aims to connect patients with reliable providers and offer self-navigation tools [States of Mind Launches a European Platform for Progressive Mental Health, Unknown]. This dual-track strategy allows it to both invest in and directly construct pieces of the infrastructure it believes is missing.
The team assembling in Lisbon
The operation is led by co-founders Yuri Filatov and Fatima Cabral, though detailed professional backgrounds for both are not extensively documented in public sources. Filatov, the CEO, is based in Lisbon and lists over 15 years of experience building from the ground up [LinkedIn, retrieved 2026] [Crunchbase, Unknown]. The team has grown to an estimated 11-50 employees, attracting talent with relevant experience [Jobs in Psychedelics].
- Product and operations. Ivan Suvorov, a product manager who joined in March 2025, previously scaled the supply side of a mental-health marketplace to over 300 providers across Europe and the UK [LinkedIn, retrieved 2026].
- Investment and partnerships. Natalia Fedulova is noted as an Investment Director and key contact, operating from San Francisco [Prospeo, April 2026].
- Clinical and regulatory expertise. Sophie Spitzer is listed as Head of the Psychedelics Hub and Co-Director of PsyStandard, an initiative driven by Pink Elephant, suggesting a focus on standards and clinical integration [Pink Elephant] [Max de Rosnay LinkedIn, retrieved 2026].
This blend of product, investment, and specialist roles indicates an attempt to build operational depth alongside capital deployment.
A capital structure built on patience
Public financial disclosure is limited. The Portuguese entity Pink Elephant, Unipessoal Lda was incorporated with a share capital of €1,000 in October 2025 [RigorBiz, October 2025]. One funding database reported the company had never raised funding as of April 2026 [Prospeo, April 2026]. This suggests the venture fund and building activities may be financed through alternative means, such as founder capital, angel backing, or a separate fund structure not yet reflected in corporate records. The absence of a disclosed institutional round underscores the early, formative stage of the build-out.
| Aspect | Detail | Source |
|---|---|---|
| Legal Entity | Pink Elephant, Unipessoal Lda | [RigorBiz, October 2025] |
| Incorporation | October 24, 2025 | [RigorBiz, October 2025] |
| Share Capital | €1,000 | [RigorBiz, October 2025] |
| Estimated Headcount | 11-50 employees | [Jobs in Psychedelics] |
| Key Product | States of Mind media & navigation platform | [LinkedIn, retrieved 2026] |
The regulatory clock is the biggest variable
The most significant risk for Pink Elephant is not competition, but time. The company’s entire model is predicated on a regulatory environment for psychedelic-assisted therapies that is still evolving, particularly in its home base of Europe. While there is momentum in places like Australia, Canada, and certain US states, broad European medical approval for substances like MDMA or psilocybin remains a future prospect. The venture builder must sustain its operations and continue building trust with patients and practitioners in a prolonged pre-revenue phase for many of its infrastructure projects.
The company’s answer appears to be a focus on the adjacent, immediate needs of mental health care today. Its recruitment materials mention tools for diagnostics, antidepressant journeys, and underserved clinical touchpoints [Jobs in Psychedelics]. By serving the current market for ketamine therapy information, provider discovery, and general mental health media, it may generate user engagement and data that retains value regardless of the pace of psychedelic regulation.
What to watch in the next twelve months
The coming year will test whether Pink Elephant can transition from blueprint to tangible traction. Key milestones will include the formal launch and user growth of its States of Mind platform, the announcement of first investments from its venture fund, and potentially a priced equity round to scale its building activities. A partnership with an established clinic network or research institution would lend credibility to its navigation tools.
For patients navigating treatment-resistant depression, PTSD, or other complex mental health conditions, the standard of care today often involves a sequential trial of medications and conventional talk therapy, a process that can take months or years with variable outcomes. Access to emerging options like legally sanctioned ketamine therapy or ongoing clinical trials is fragmented and difficult to navigate. Pink Elephant is betting that the individuals enduring this wait are already seeking better information and pathways. Its success hinges on becoming their trusted guide long before a prescription is ever written.
Sources
- [Pink Elephant, October 2026] Pink Elephant | https://pink-elephant.co/
- [Remocate, September 2025] CMO for Pink Elephant VC | https://www.remocate.app/jobs/cmo-3
- [LinkedIn, retrieved 2026] Yuri Filatov - co-founder and CEO | https://www.linkedin.com/in/filalogic
- [Jobs in Psychedelics] Pink Elephant company profile | https://jobsinpsychedelics.com/companies/pink-elephant
- [RigorBiz, October 2025] Pink Elephant, Unipessoal Lda | https://www.rigorbiz.pt/pink-elephant-unipessoal-lda
- [Crunchbase, Unknown] Fatima Cabral - Co-Founder and CEO @ Pink Elephant | https://www.crunchbase.com/person/fatima-cabral-2a09
- [Prospeo, April 2026] Pink Elephant | https://prospeo.io/c/pink-elephant
- [LinkedIn, retrieved 2026] Ivan Suvorov - product manager | https://www.linkedin.com/in/ivansuvorov
- [States of Mind Launches a European Platform for Progressive Mental Health, Unknown] States of Mind Launches a European Platform for Progressive Mental Health |
- [Max de Rosnay LinkedIn, retrieved 2026] Max de Rosnay LinkedIn | https://www.linkedin.com/in/max-derosnay